Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

2(40.0%)

Phase 4

1(20.0%)

Phase 3

1(20.0%)

Phase 1

1(20.0%)

5Total

Phase 2(2)

Phase 4(1)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT00527475Phase 2Completed

Ranibizumab and Reduced Fluence PDT for AMD

Role: lead

NCT01295112Phase 2Completed

Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion

Role: lead

NCT05486468Phase 3Recruiting

The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment

Role: lead

NCT03984110Phase 4Completed

One Year Trial Evaluating Safety of Ozurdex With Eylea

Role: lead

NCT01728883Completed

Diabetic Retinopathy And the Myvisiontrack® (DRAMA) Study

Role: collaborator

NCT00570479Phase 1Completed

Prophylactic Anecortave Acetate in Patients With a Retisert Implant

Role: lead

All 6 trials loaded